Trial Profile
An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 22 May 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
- 01 Apr 2019 Status changed from active, no longer recruiting to completed.
- 02 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.